Clinical trials: Type 2 Diabetic Patients
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in Sweden to assess the effect of Omega-3 carboxylic acids and dapagliflozin on liver fat in patients with…
- Trial name
- EFFECTII (NCT02279407)
- Testing
- Omega-3 carboxylic acids, Dapagliflozin
- Where
- 5 sites in Sweden
- Volunteers
- 223 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet…
- Trial name
- NCT00367055
- Testing
- rosiglitazone-metformin, Metformin, metformin+ gliclazide
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea
The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not…
- Trial name
- NCT04980040
- Testing
- Alogliptin Benzoate
- Where
- 22 sites in South Korea
- Volunteers
- 3,623 people
- Sponsor
- Takeda
Covid19
AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.
- Trial name
- ARCADIA (NCT04516759)
- Testing
- AZD1656
- Where
- 30 sites in Czechia, Romania and 1 more
- Volunteers
- 170 people
- Sponsor
- St George Street Capital
Diabetes Mellitus, Type 2
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of…
- Trial name
- NCT00900146
- Testing
- Canakinumab, Metformin
- Where
- 106 sites in United States, Argentina and 12 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Type 2 Diabetes, Overt Diabetic Nephropathy
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Objective: To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.
- Trial name
- NCT00324675
- Testing
- Rosiglitazone
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Technische Universität Dresden
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of TA-7284 orally administered once daily for 15 days (1 day followed by a 1 day washout period and then 14 consecutive days).
- Trial name
- NCT00707954
- Testing
- TA-7284
- Where
- Japan
- Volunteers
- 61 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients…
- Trial name
- NCT01087502
- Testing
- Glimepiride, Linagliptin
- Where
- 52 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.
- Trial name
- NCT00819091
- Testing
- BI 1356
- Where
- 45 sites in United States, Argentina and 5 more
- Volunteers
- 245 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with…
- Trial name
- NCT00360334
- Testing
- exenatide, insulin glargine
- Where
- 31 sites in United Kingdom
- Volunteers
- 235 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment as add-on therapy to metformin in…
- Trial name
- NCT01215097
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 306 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic
The current study was to develop a software "Line@" based health education program, providing video-based health information and communication between diabetes patients and health-care professionals.
- Trial name
- NCT04876274
- Testing
- TMU-LOVE
- Where
- Taiwan
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Type 2 Diabetes Mellitus, Insulin Resistance
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in general represent important gaps in knowledge to better understand the etiopathogenesis of T2D.
- Trial name
- NCT02597101
- Testing
- Metformin, saxagliptin, AZD9668
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nick Giannoukakis, PhD
Diabetic Neuropathy
Alpha Lipoic Acid for Treatment of Diabetic Neuropathy
Patients with diabetic neuropathy and total symptoms score(TSS) >7 points were invited to this open multicenter study. Patients were free of pain medications and severe diabetic complications .Patients started alpha lipoic acid…
- Trial name
- NCT02439879
- Testing
- Alpha lipoic acid
- Volunteers
- 45 people
- Sponsor
- Universidad Popular Autónoma del Estado de Puebla
Type 2 Diabetes Mellitus
An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients
Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin…
- Trial name
- NCT02435277
- Testing
- Low Metformin, Mid Metformin, High Metformin
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- NuSirt Biopharma
Diabetes Mellitus, Type 2
Treatment of GLP-1 for Diabetic Bariatric Patients
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process.
- Trial name
- NOVO-GLP1 (NCT04624672)
- Testing
- Semaglutide (1 Mg Dose)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Geisinger Clinic
Type 2 Diabetes, Healthy
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin sensitivity in skeletal muscle, liver, and fat cells.
- Conditions
- Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
- Trial name
- PIO-EX (NCT00845182)
- Testing
- Pioglitazone, Exenatide, Pioglitazone and Exenatide
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic